Literature DB >> 32828215

Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.

Megan Othus1, Aasthaa Bansal2, Harry Erba3, Scott Ramsey4.   

Abstract

OBJECTIVES: When populations contain mixtures of cured and uncured patients, the use of traditional parametric approaches to estimate overall survival (OS) can be biased. Mixture cure models may reduce bias compared with traditional parametric models, but their accuracy is subject to certain conditions. Importantly, mixture cure models assume that that there is enough follow-up to identify individuals censored at the end of the follow-up period as cured. The purpose of this article is to describe biases that can occur when mixture cure models are used to estimate mean survival from data with limited follow-up.
METHODS: We analyzed 6 trials conducted by the SWOG Cancer Research Network Leukemia Committee. For each trial, we analyzed 2 data sets: the data released to the committee when the results of the trial were unblinded and a second data set with additional follow-up. We estimated mean OS using parametric survival models with and without a cure fraction.
RESULTS: When using mixture cure models, in 4 trials, estimates of mean OS were higher with the first analysis (with limited follow-up) compared with estimates from data with longer follow-up. In 1 trial, the reverse pattern was observed. In 1 trial, the cure estimate changed little with additional follow-up.
CONCLUSIONS: Caution should be taken when using mixture cure models in scenarios with limited follow-up. The biases resulting from fitting these models may be exacerbated when the models are being used to extrapolate OS and estimate mean OS.
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cure models; oncology; overall survival; survival analysis

Mesh:

Year:  2020        PMID: 32828215      PMCID: PMC7446760          DOI: 10.1016/j.jval.2020.02.015

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  17 in total

1.  Accounting for Cured Patients in Cost-Effectiveness Analysis.

Authors:  Megan Othus; Aasthaa Bansal; Lisel Koepl; Samuel Wagner; Scott Ramsey
Journal:  Value Health       Date:  2016-06-09       Impact factor: 5.725

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.

Authors:  Joshua A Roth; Sean D Sullivan; Vincent W Lin; Aasthaa Bansal; Anna G Purdum; Lynn Navale; Paul Cheng; Scott D Ramsey
Journal:  J Med Econ       Date:  2018-10-16       Impact factor: 2.448

4.  Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models.

Authors:  Aasthaa Bansal; Sean D Sullivan; Vincent W Lin; Anna G Purdum; Lynn Navale; Paul Cheng; Scott D Ramsey
Journal:  Med Decis Making       Date:  2019-02-28       Impact factor: 2.583

5.  A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

Authors:  Sucha Nand; Megan Othus; John E Godwin; Cheryl L Willman; Thomas H Norwood; Dianna S Howard; Steven E Coutre; Harry P Erba; Frederick R Appelbaum
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

6.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

7.  A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Jerald P Radich; Kenneth J Kopecky; Frederick R Appelbaum; Suzanne Kamel-Reid; Wendy Stock; Greg Malnassy; Elisabeth Paietta; Martha Wadleigh; Richard A Larson; Peter Emanuel; Martin Tallman; Jeff Lipton; A Robert Turner; Michael Deininger; Brian J Druker
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

8.  Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Authors:  Mikkael A Sekeres; Megan Othus; Alan F List; Olatoyosi Odenike; Richard M Stone; Steven D Gore; Mark R Litzow; Rena Buckstein; Min Fang; Diane Roulston; Clara D Bloomfield; Anna Moseley; Aziz Nazha; Yanming Zhang; Mario R Velasco; Rakesh Gaur; Ehab Atallah; Eyal C Attar; Elina K Cook; Alyssa H Cull; Michael J Rauh; Frederick R Appelbaum; Harry P Erba
Journal:  J Clin Oncol       Date:  2017-05-09       Impact factor: 50.717

9.  Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.

Authors:  Melanie D Whittington; R Brett McQueen; Daniel A Ollendorf; Varun M Kumar; Richard H Chapman; Jeffrey A Tice; Steven D Pearson; Jonathan D Campbell
Journal:  JAMA Netw Open       Date:  2019-02-01

Review 10.  Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods.

Authors:  Christopher Jackson; John Stevens; Shijie Ren; Nick Latimer; Laura Bojke; Andrea Manca; Linda Sharples
Journal:  Med Decis Making       Date:  2016-07-10       Impact factor: 2.583

View more
  1 in total

1.  Controlled variable selection in Weibull mixture cure models for high-dimensional data.

Authors:  Han Fu; Deedra Nicolet; Krzysztof Mrózek; Richard M Stone; Ann-Kathrin Eisfeld; John C Byrd; Kellie J Archer
Journal:  Stat Med       Date:  2022-07-06       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.